Many patients starting GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) wonder about this potential side effect
Obesity prevalence has doubled since 1990, with one in eight individuals being obese worldwide
In Phase II trials, retatrutide achieved up to 24.2% weight loss over 48 weeks, significantly outperforming existing therapies
The choice between semaglutide and tirzepatide depends on multiple factors including your specific health profile, insurance coverage, and treatment goals
Stephen Geldart Head of Analysis James Brittain Director, Head of Advisory Contact us "*" indicates required fields
Supplements wont get you there Inno Shred GLP-1 is built from vitamins, plant extracts, and stimulants, but none of its ingredients are FDA-approved GLP-1 agonist medications like semaglutide or tirzepatide